Wells Fargo analyst Mohit Bansal raised the firm’s price target on Regeneron to $980 from $875 and keeps an Overweight rating on the shares. The firm has a bullish stance on conversion to HD Eylea even before the J-code, and Wells Fargo sees upside to consensus, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron price target raised to $1,050 from $950 at Oppenheimer
- Regeneron price target raised to $925 from $900 at Barclays
- Regeneron announces FDA approval of Eylea HD for three indications
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)